Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - klisyri
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp9a837e87c0c475b218e0535edae8bbad
identifier: http://ema.europa.eu/identifier
/EU/1/21/1558/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Klisyri 10 mg/g ointment
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-9a837e87c0c475b218e0535edae8bbad
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1558/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - klisyri
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Klisyri contains the active substance tirbanibulin. It is used for the treatment of mild actinic keratosis in adults. Actinic keratosis is a rough area of skin that has developed in people who have been exposed to too much sunshine over a long time. Klisyri should only be used for flat actinic keratosis on the face and scalp.
Do not use Klisyri
Warnings and precautions
Talk to your doctor or pharmacist before using Klisyri
Children and adolescents Do not give this medicine to children and adolescents under 18 years of age because they do not get actinic keratosis.
Other medicines and Klisyri Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
If you have previously used Klisyri or similar medicines, tell your doctor before starting the treatment.
Pregnancy, breast-feeding, and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Klisyri should not be used during pregnancy.
Driving and using machines This medicine is not expected to have any effect on your ability to drive or to use machines.
Klisyri contains propylene glycol
Propylene glycol may cause skin irritation
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
This medicine is intended to treat an area of up to 25 cm2 for only one treatment course of five days. If the treated area does not show complete clearance at about 8 weeks after the treatment cycle started, or new lesions develop within the treatment area, the treatment should be reconsidered by your doctor and other treatment options should be considered.
Apply a thin layer of Klisyri to the affected area on the face or scalp once daily for 5 days in a row. One sachet contains enough ointment to cover the treatment area. Do not save the opened sachet for use on another day, even if there is still ointment left.
Application instructions:
If you use more Klisyri than you should Wash the treated area with mild soap and water. Please contact your doctor or pharmacist if you get severe skin reactions.
If you forget to use Klisyri
If you miss a dose, apply the ointment as soon as you remember and then continue with your regular schedule. Do not apply the ointment more than once a day.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
After using this medicine, you may get side effects on the skin where you apply the ointment. These side effects may get worse for up to 8 days after you start the treatment, and they typically go away within 2 to 3 weeks after completing the treatment. Contact your doctor if these side effects get severe.
The most frequently occurring side effects in the treated area:
Very common (may affect more than 1 in 10 people)
Other possible side effects in the treated area:
Common (may affect up to 1 in 10 people)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not refrigerate or freeze.
Do not use this medicine after the expiry date which is stated on the outer carton and the label after EXP. The expiry date refers to the last day of that month.
For single use only. Do not re-use the sachets once opened.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Klisyri contains
Marketing Authorisation Holder
Almirall, S.A. Ronda General Mitre, 08022 Barcelona
Spain
Manufacturer Almirall Hermal GmbH Scholtzstrasse 3 21465 Reinbek Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien/ Luxembourg/Luxemburg
Almirall N.V. T l/Tel: +32 (0)2 771 86 sland
Vistor hf. S mi: +354 535 70 / esk republika/ Eesti/ / Espa a/ Hrvatska/ / Latvija/ Lietuva/ Magyarorsz g/ Malta/ Rom nia/ Slovenija/ Slovensk republika
Almirall, S.A. Te ./ Tel/ : +34 93 291 30 Tel ( esk republika / Slovensk republika): +420 220 990 Italia
Almirall SpA Tel.: +39 02 346Danmark/ Norge/ Suomi/Finland/ Sverige
Almirall ApS Tlf/ Puh/Tel: +45 70 25 75 Nederland
Almirall B.V. Tel: +31 (0)307991Deutschland
sterreich
Almirall Hermal GmbH Tel.: +49 (0)40 72704-0
Almirall GmbH Tel.: +43 (0)1/595 39 France
Almirall SAS, 1 T l.: +33(0)1 46 46 19 Polska
Almirall Sp.z o. o. Tel.: +48 22 330 02 Ireland/ United Kingdom (Northern Ireland) Almirall, S. A. Tel: +353 (0) 1431 9Portugal
Almirall - Produtos Farmac uticos, Lda.
Tel.: +351 21 415 57 This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-9a837e87c0c475b218e0535edae8bbad
Resource Composition:
Generated Narrative: Composition composition-en-9a837e87c0c475b218e0535edae8bbad
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1558/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - klisyri
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp9a837e87c0c475b218e0535edae8bbad
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp9a837e87c0c475b218e0535edae8bbad
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1558/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Klisyri 10 mg/g ointment
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en